Salidroside ameliorates Adriamycin nephropathy in mice by inhibiting β-catenin activity
Salidroside ameliorates Adriamycin nephropathy in mice by inhibiting β-catenin activity
复制标题
红景天苷通过抑制 β-catenin 活性改善小鼠阿霉素肾病
DOI：
10.1111/jcmm.14340
复制
发表时间：
2019-06-01
影响因子：
5.3
通讯作者：
Sun, Cheng
中科院分区：
文献类型：
--
作者：
Huang, Xinzhong;Xue, Haiyan;Sun, Cheng
Salidroside is a major phenylethanoid glycoside in Rhodiola rosea L., a traditional Chinese medicine, with multiple biological activities. It has been shown that salidroside possesses protective effects for alleviating diabetic renal dysfunction, contrastinduced-nephropathy and other kidney diseases. However, the involved molecular mechanism was still not understood well. Herein, we examined the protective effects of salidroside in mice with Adriamycin (ADR)-induced nephropathy and the underlying molecular mechanism. The results showed that salidroside treatment ameliorates proteinuria; improves expressions of nephrin and podocin; and reduces kidney fibrosis and glomerulosclerosis induced by ADR. Mechanistically, ADR induces a robust accumulation of beta-catenin in the nucleus and stimulates its downstream target gene expression. The application of salidroside largely abolishes the nuclear translocation of beta-catenin and thus inhibits its activity. Furthermore, the activation of beta-catenin almost completely counteracts the protective roles of salidroside in ADR-injured podocytes. Taken together, our data indicate that salidroside ameliorates proteinuria, renal fibrosis and podocyte injury in ADR nephropathy, which may rely on inhibition of beta-catenin signalling pathway.
